# EDGAR Filing Document

**Accession Number:** 0001265521
**File Stem:** 0001493152-26-007149
**Filing Date:** 2026-2
**Character Count:** 4448
**Document Hash:** c72531df8cef63610202b90e910cc423
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-007149.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001493152-26-007149

**CONFORMED SUBMISSION TYPE**: PRER14C

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Polomar Health Services, Inc.
- **CENTRAL INDEX KEY:** 0001265521
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 861006313
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** PRER14C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56555
- **FILM NUMBER:** 26642301

**BUSINESS ADDRESS:**
- **STREET 1:** 32866 US HWY. 19 N
- **CITY:** PALM HARBOR
- **STATE:** FL
- **ZIP:** 34684
- **BUSINESS PHONE:** 800-490-7454

**MAIL ADDRESS:**
- **STREET 1:** 32866 US HWY. 19 N
- **CITY:** PALM HARBOR
- **STATE:** FL
- **ZIP:** 34684

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Trustfeed Corp.
- **DATE OF NAME CHANGE:** 20230504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEALTHMED SERVICES LTD
- **DATE OF NAME CHANGE:** 20031001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14C**

**(Amendment No. 1)**

**(RULE 14c-101)**

**SCHEDULE 14C INFORMATION**

**Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934**

Check the appropriate box:

☒ Preliminary Information Statement <br> ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) <br> ☐ Definitive Information Statement

**POLOMAR HEALTH SERVICES INC.**

**(Name of Registrant as Specified in its Charter)**

 ****

Payment of Filing Fee (Check all boxes that apply):

☐ No fee required

☐ Fee paid previously with preliminary materials.

☒ Fee computed on table in exhibit required by Item 25(b) of Schedule 14A (17 CFR 240.14a-101) per Item 1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11.

**EXPLANATORY NOTE**

This Amendment No. 1 ("Amendment No. 1") to the information statement on Schedule 14C ("Information Statement") is being filed by Polomar Health Services, Inc. (the "Company") to include Exhibit 107 to the preliminary information statement on Schedule 14C filed with the Securities and Exchange Commission (the "SEC") on February 5, 2026.

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**CALCULATION OF FILING FEE TABLES**

**Schedule 14C**

(Form Type)

**Polomar Health Services, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Transaction Valuation**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Proposed Maximum**<br> **Aggregate Value of Transaction** |  | **Fee rate** | **Amount of**<br> **Filing Fee** |
| Fees to Be Paid | $39789000 | (1) | 0.00013810 | $5494.86 |
| Fees Previously Paid | $0 |  |  | $0 |
| **Total Transaction Valuation** | $39789000 |  |  |  |
| **Total Fees Due for Filing** |  |  |  | $5494.86 |
| **Total Fees Previously Paid** |  |  |  | $0 |
| **Total Fee Offsets** |  |  |  | $0 |
| **Net Fee Due** |  |  |  | $5494.86 |

---

---

| | |
|:---|:---|
| (1)<br>| For accounting purposes, the purchase price represents the fair value of the equity interest Altanine, as the accounting acquirer, would have had to issue to give the owners of the legal acquirer (i.e. Polomar) the same ownership interest they hold after the Merger.<br>|
|  | Although Polomar's shares traded at $0.20 on the OTC market, management concluded this price was not representative of fair value due to minimal trading volume and the company's nominal net assets. Instead, the fair value of the consideration transferred was determined based on an independent valuation as of July 23, 2025 of the combined entity, which implied a total post-merger equity value of $200.7 million. Given Polomar legacy shareholders' 19% ownership interest, the fair value of the equity interest acquired (i.e., the consideration transferred) was estimated at $39,789,000 million, including approximately $598k of assumed interest-bearing debt and $407k of assumed non-interest liabilities. The independent valuation has not been finalized or audited. Additionally, such valuation may be amended and/or updated at the time of the closing of the merger; however, the Company does not anticipate the consideration to be materially different. |

---

N/A